JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Simulations Plus Inc

Fechado

SetorSaúde

14.52 2.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.42

Máximo

14.6

Indicadores-chave

By Trading Economics

Rendimento

3.9M

4.5M

Vendas

5.9M

24M

EPS

0.35

Rendimento de Dividendos

0.48

Margem de lucro

18.669

Funcionários

212

EBITDA

4.9M

7.2M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.89% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.48%

2.24%

Próximos Ganhos

13 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

51M

302M

Abertura anterior

12.41

Fecho anterior

14.52

Sentimento de Notícias

By Acuity

26%

74%

88 / 348 Ranking em Healthcare

Simulations Plus Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2026, 19:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek Group Rejects EQT's Revised Offer

24 de abr. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Scoring the Cook Era -- Barrons.com

24 de abr. de 2026, 20:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

24 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

24 de abr. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 20:09 UTC

Ganhos

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 de abr. de 2026, 19:48 UTC

Conversa de Mercado
Notícias Principais

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 de abr. de 2026, 19:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 19:25 UTC

Aquisições, Fusões, Aquisições de Empresas

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 de abr. de 2026, 19:22 UTC

Ganhos

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 de abr. de 2026, 19:06 UTC

Ganhos

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 de abr. de 2026, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 de abr. de 2026, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 de abr. de 2026, 18:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek Rejects Revised EQT Offer

24 de abr. de 2026, 18:12 UTC

Conversa de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 de abr. de 2026, 18:06 UTC

Conversa de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 de abr. de 2026, 17:42 UTC

Ganhos

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 de abr. de 2026, 17:28 UTC

Ganhos

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 de abr. de 2026, 17:28 UTC

Conversa de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 de abr. de 2026, 17:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de abr. de 2026, 17:11 UTC

Conversa de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 de abr. de 2026, 17:09 UTC

Conversa de Mercado
Ganhos

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 de abr. de 2026, 17:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 17:06 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 de abr. de 2026, 16:51 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

24 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Simulations Plus Inc Previsão

Preço-alvo

By TipRanks

9.89% parte superior

Previsão para 12 meses

Média 16 USD  9.89%

Máximo 16 USD

Mínimo 16 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Simulations Plus Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

88 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat